Covers 3 stories
**First and only combination regimen to demonstrate statistically significant and clinically meaningful improvements in RFS and DMFS compared to KEYTRUDA alone for these patients..., **Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA**® **Met Endpoints of Recurrence-Free Survival \(RFS\) and Distant Metastasis-Free..., and more ›